Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Algernon Pharmaceuticals (AGN) has awarded a contract to begin the manufacturing of a cGMP supply of its repurposed drug candidate NP-251
  • The company has also announced a new chronic kidney disease research program
  • CEO Chris Moreau sat down with Shoran Devi to discuss the news
  • Algernon is a drug re-purposing company that investigates already approved drugs for new disease applications
  • Shares of Algernon Pharmaceuticals Inc. (AGN) opened trading at C$5.55

Algernon Pharmaceuticals (AGN) has awarded a contract to begin the manufacturing of a cGMP supply of its repurposed drug candidate NP-251 (Repirinast).

The contract was awarded to Zhejiang Ausun Pharmaceutical CO, LTD of China.

Repirinast was originally marketed in Japan under the brand name Romet™ for the treatment of asthma.

The company has also announced a new chronic kidney disease research program.

CEO Chris Moreau sat down with Shoran Devi to discuss the news.

Algernon is a drug re-purposing company that investigates safe, already approved drugs, including naturally occurring compounds, for new disease applications.

Shares of Algernon Pharmaceuticals Inc. (AGN) opened trading at C$5.55.

More From The Market Herald

" This Company is Discovering More Gold in Ecuador, with its Copper Story Just Starting

While gold production in countries such as Peru, — which is South America’s leading gold producer — Brazil, Colombia, Bolivia and Argentina dominate
The Market Herald Video

" Midnight Sun (TSXV:MMA) shares plans for Solwezi Licences

Midnight Sun Mining Corp. (MMA) has announced that Zambian-Congo Copperbelt expert, Dr. Simon Dorling, has agreed to work with the company.
The Market Herald Video

" Trillion Energy (CSE:TCF) closes $22.5M public offering

Trillion Energy (TCF) has closed its previously announced public offering for gross proceeds of $22,486,439.